State Street Corp lifted its position in shares of Codexis, Inc. (NASDAQ:CDXS) by 26.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 580,623 shares of the biotechnology company’s stock after buying an additional 122,757 shares during the quarter. State Street Corp owned approximately 1.41% of Codexis worth $3,168,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Nationwide Fund Advisors boosted its position in Codexis by 15.7% during the second quarter. Nationwide Fund Advisors now owns 21,568 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 2,928 shares in the last quarter. Bank of America Corp DE boosted its position in Codexis by 2.9% during the first quarter. Bank of America Corp DE now owns 25,477 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 717 shares in the last quarter. Rhumbline Advisers boosted its position in Codexis by 23.3% during the second quarter. Rhumbline Advisers now owns 42,872 shares of the biotechnology company’s stock valued at $234,000 after purchasing an additional 8,095 shares in the last quarter. White Pine Capital LLC bought a new stake in Codexis during the second quarter valued at about $277,000. Finally, Teachers Advisors LLC boosted its position in Codexis by 16.5% during the second quarter. Teachers Advisors LLC now owns 67,569 shares of the biotechnology company’s stock valued at $368,000 after purchasing an additional 9,552 shares in the last quarter. 65.71% of the stock is currently owned by institutional investors and hedge funds.
In other Codexis news, major shareholder Ventures Vii Affiliates F. Vivo sold 1,060,000 shares of the firm’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $5.78, for a total value of $6,126,800.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 9.80% of the stock is currently owned by company insiders.
A number of equities research analysts recently weighed in on CDXS shares. ValuEngine raised Codexis from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. HC Wainwright raised their price objective on Codexis from $8.00 to $8.50 and gave the company a “buy” rating in a research report on Friday, October 13th. BidaskClub raised Codexis from a “sell” rating to a “hold” rating in a report on Saturday, August 19th. Jefferies Group reissued a “buy” rating and issued a $9.00 price target (up previously from $8.00) on shares of Codexis in a report on Monday, October 2nd. Finally, Zacks Investment Research downgraded Codexis from a “hold” rating to a “sell” rating in a report on Monday, September 4th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Codexis has an average rating of “Hold” and a consensus target price of $7.50.
Shares of Codexis, Inc. (CDXS) opened at $6.85 on Monday. Codexis, Inc. has a twelve month low of $3.60 and a twelve month high of $7.95.
COPYRIGHT VIOLATION WARNING: “State Street Corp Purchases 122,757 Shares of Codexis, Inc. (CDXS)” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/11/state-street-corp-purchases-122757-shares-of-codexis-inc-cdxs.html.
Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.
Receive News & Ratings for Codexis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.